Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Colorectal Neoplasms 8Stomach Neoplasms 6Carcinoma, Hepatocellular 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Esophageal Squamous Cell Carcinoma 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Resected Liver Metastases From Colorectal Cancer 1Recurrence 1Quality of Life 1Oesophagogastric Cancer 1Malignant Tumor of Pancreas Metastatic to Liver 1Inflammatory Breast Neoplasms 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Gastroesophageal Junction Adenocarcinoma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Breast Diseases 1Bile Duct Neoplasms 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 2Taxes 1Neoadjuvant Therapy 1Letrozole 1Lapatinib 1Gonadotropin-Releasing Hormone 1Doxorubicin 1Cisplatin 1Carboplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Inflammatory Breast Neoplasms × Capecitabine × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡